Biotage Joins Forces with MultiSynTech and Enters the Peptide Synthesis Business
News Feb 24, 2009
Biotage announced that the company will enter the peptide synthesis business, through two new agreements with German company MultiSynTech GmbH. The agreements concern both the distribution rights for MultiSynTechs systems and the establishment of a joint development project.
The agreements with MultiSynTech will grant Biotage distribution rights for all current MultiSynTech peptide synthesis systems. Biotage and MultiSynTech have also agreed on a joint development project to design and market a new microwave-aided peptide synthesis system, which will increase yield and speed in peptide synthesis.
Demand for synthetic peptides is currently growing rapidly. The peptide synthesizer market is estimated at SEK 150m and is growing at double digit rate. In the research phase, biochemists need increasingly longer, more complex peptides to study protein interactions, produce peptide antibodies, and understand complex disease states. As the number and complexity of peptides increase, the biochemists need new tools that offer higher productivity and increased performance.
The Biotage - MultiSynTech collaboration will create those new tools that University and biopharmaceutical peptide research groups and contract peptide labs need to meet the new challenges in peptide synthesis. Biotage will be uniquely positioned to offer both parallel synthesis and microwave synthesis capability to address the full range of needs.
We look forward to working in close collaboration with Biotage. Biotage has a proven sales and support team that dramatically expands our coverage outside Central Europe, and really opens opportunities for our current products in USA, UK, Nordic and Asian regions, says Udo Treffer, CEO of MultiSynTech.
Five percent of acute leukemia cases are diagnosed as mixed lineage leukemia (MLL). MLL is an aggressive blood cancer that predominantly occurs in infants and has been difficult to treat. Now, researchers have identified a very common protein as the single key to the cascade of events leading to MLL. Shutting down this protein may be a cure.READ MORE
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019
6th World Congress on Human Genetics and Genetic Diseases
Apr 08 - Apr 09, 2019